T2 Biosystems (TTOO) Announces Second Largest Sale of Sepsis-Focused Instruments in Company History
T2 Biosystems, Inc. (NASDAQ:), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the second largest sale of sepsis-focused T2Dx® instruments of the company’s history.
T2 Biosystems’ distribution partner, Biomedica Poland, has been awarded a multi-year contract for T2Dx instruments and sepsis test panels to be deployed in selected hospitals across Poland. The initial order includes seven T2Dx instruments, valued at over $450,000, with the possibility that nine additional instruments will be sold and deployed to more hospitals in Poland in the second half of 2023. The initial term of the contract guaranteed by our distributor is for three years, with the possibility of extension for another two years.
“We are delighted with this order and look forward to working closely with our distribution partner, Biomedica Poland, to provide our state-of-the-art sepsis diagnostic products to hospitals across Poland,” said John Sperzel. , Chairman and CEO of T2 Biosystems. . “Our sepsis testing revenue grew 67% in Central Europe in the first quarter of 2023, compared to the prior year period, and we believe there is tremendous potential to further expand the adoption of our sepsis products in Poland and throughout Europe.”
Poland is the fifth most populous member state of the European Union, with more than 40 million inhabitants, and has more than 1,200 hospitals. Based on the results of a 2020 survey of hospitals in Poland, it was concluded that “there is room for improvement in the management of sepsis and early septic shock”. A study of severe sepsis in intensive care patients in Poland found mortality rates of 46% to 54% and length of ICU stay ranging from 8 to 13 days in intensive care. The introduction of the company’s T2Dx instrument and sepsis test panels enables rapid detection of sepsis-causing pathogens and antibiotic resistance genes, in just 3-5 hours, potentially enabling clinicians to achieve faster targeted antimicrobial therapy, reduce length of hospital stay and improve patient outcomes .
